Top

Journal of Endocrinological Investigation

22-04-2024 | Androgens | Original Article

Preconceptional maternal hyperandrogenism and metabolic syndrome risk in male offspring: a long-term population-based study

Authors: M. Noroozzadeh, M. Rahmati, M. Amiri, M. Saei Ghare Naz, F. Azizi, F. Ramezani Tehrani

Published in: Journal of Endocrinological Investigation

Abstract

Purpose

There is limited research on the effects of maternal hyperandrogenism (MHA) on cardiometabolic risk factors in male offspring. We aimed to compare the risk of metabolic syndrome (MetS) in sons of women with preconceptional hyperandrogenism (HA) to those of non-HA women in later life.

Methods

Using data obtained from the Tehran Lipid and Glucose Cohort Study, with an average of 20 years follow-up, 1913 sons were divided into two groups based on their MHA status, sons with MHA (n = 523) and sons without MHA (controls n = 1390). The study groups were monitored from the baseline until either the incidence of events, censoring, or the end of the study period, depending on which occurred first. Age-scaled unadjusted and adjusted Cox regression models were utilized to evaluate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between MHA and MetS in their sons.

Results

There was no significant association between MHA and HR of MetS in sons with MHA compared to controls, even after adjustment (unadjusted HR (95% CI) 0.94 (0.80–1.11), P = 0.5) and (adjusted HR (95% CI) 0.98 (0.81–1.18), P = 0.8). Sons with MHA showed a HR of 1.35 for developing high fasting blood sugar compared to controls (unadjusted HR (95% CI) 1.35 (1.01–1.81), P = 0.04), however, after adjustment this association did not remain significant (adjusted HR (95% CI) 1.25 (0.90–1.74), P = 0.1).

Conclusion

The results suggest that preconceptional MHA doesn’t increase the risk of developing MetS in sons in later life. According to this suggestion, preconceptional MHA may not have long-term metabolic consequences in male offspring.

Naseri P, Khodakarim S, Guity K, Daneshpour MS (2018) Familial aggregation and linkage analysis with covariates for metabolic syndrome risk factors. Gene 659:118–122. https://doi.org/10.1016/j.gene.2018.03.033CrossRefPubMed

Ramirez-Velez R (2012) In utero fetal programming and its impact on health in adulthood. Endocrinol Nutr 59:383–393. https://doi.org/10.1016/j.endonu.2012.02.002CrossRefPubMed

Roland AV, Nunemaker CS, Keller SR, Moenter SM (2010) Prenatal androgen exposure programs metabolic dysfunction in female mice. J Endocrinol 207:213–223. https://doi.org/10.1677/joe-10-0217CrossRefPubMedPubMedCentral

Sherman SB, Sarsour N, Salehi M, Schroering A, Mell B (2018) Prenatal androgen exposure causes hypertension and gut microbiota dysbiosis. Gut Microbes 9:400–421. https://doi.org/10.1080/19490976.2018.1441664CrossRefPubMedPubMedCentral

Noroozzadeh M, Rahmati M, Behboudi-Gandevani S, Ramezani Tehrani F (2022) Maternal hyperandrogenism is associated with a higher risk of type 2 diabetes mellitus and overweight in adolescent and adult female offspring: a long-term population-based follow-up study. J Endocrinol Invest 45:963–972. https://doi.org/10.1007/s40618-021-01721-2CrossRefPubMed

Noroozzadeh M, Rahmati M, Farhadi-Azar M, Saei Ghare Naz M, Azizi F, Ramezani Tehrani F (2023) Maternal androgen excess increases the risk of metabolic syndrome in female offspring in their later life: a long-term population-based follow-up study. Arch Gynecol Obstet 308:1555–1566. https://doi.org/10.1007/s00404-023-07132-3CrossRefPubMed

Puttabyatappa M, Padmanabhan V (2017) Prenatal testosterone programming of insulin resistance in the female sheep. Adv Exp Med Biol 1043:575–596. https://doi.org/10.1007/978-3-319-70178-3_25CrossRefPubMed

Manti M, Fornes R, Pironti G, McCann Haworth S, Zhengbing Z, Benrick A, Carlström M, Andersson D, Stener-Victorin E (2020) Maternal androgen excess induces cardiac hypertrophy and left ventricular dysfunction in female mice offspring. Cardiovasc Res 116:619–632. https://doi.org/10.1093/cvr/cvz180CrossRefPubMed

Azizi F, Madjid M, Rahmani M, Emami H, Mirmiran P, Hadjipour R (2000) Tehran Lipid and Glucose Study (TLGS): rationale and design. Iranian J Endocrinol Metabol 2:77–86

10.

Ramezani Tehrani F, Behboudi-Gandevani S, Rostami Dovom M, Farahmand M, Minooee S, Noroozzadeh M, Amiri M, Nazarpour S, Azizi F (2018) Reproductive assessment: findings from 20 years of the tehran lipid and glucose study. Int J Endocrinol Metab 16:e84786. https://doi.org/10.5812/ijem.84786CrossRefPubMedPubMedCentral

11.

Tehrani FR, Rashidi H, Azizi F (2011) The prevalence of idiopathic hirsutism and polycystic ovary syndrome in the Tehran Lipid and Glucose Study. Reprod Biol Endocrinol 9:144. https://doi.org/10.1186/1477-7827-9-144CrossRefPubMedPubMedCentral

12.

Asghari G, Yuzbashian E, Mirmiran P, Hooshmand F, Najafi R, Azizi F (2016) Dietary approaches to stop hypertension (dash) dietary pattern is associated with reduced incidence of metabolic syndrome in children and adolescents. J Pediatr 174:178-184.e171. https://doi.org/10.1016/j.jpeds.2016.03.077CrossRefPubMed

13.

Griffin BA, Anderson GL, Shih RA, Whitsel EA (2012) Use of alternative time scales in Cox proportional hazard models: implications for time-varying environmental exposures. Stat Med 31:3320–3327. https://doi.org/10.1002/sim.5347CrossRefPubMedPubMedCentral

14.

Zhang Z (2016) Multiple imputation for time series data with Amelia package. Ann Transl Med 4:56. https://doi.org/10.3978/j.issn.2305-5839.2015.12.60CrossRefPubMedPubMedCentral

15.

Ozanne SE (2001) Metabolic programming in animals. Br Med Bull 60:143–152. https://doi.org/10.1093/bmb/60.1.143CrossRefPubMed

16.

Barker DJ (2004) The developmental origins of chronic adult disease. Acta Paediatr 93:26–33CrossRef

17.

Goldstein JM, Hale T, Foster SL, Tobet SA (2019) Sex differences in major depression and comorbidity of cardiometabolic disorders: impact of prenatal stress and immune exposures. Neuropsychopharmacology 44:59–70. https://doi.org/10.1038/s41386-018-0146-1CrossRefPubMed

18.

Rinaudo P, Wang E (2012) Fetal programming and metabolic syndrome. Annu Rev Physiol 74:107–130. https://doi.org/10.1146/annurev-physiol-020911-153245CrossRefPubMed

19.

Osmond C, Barker DJ (1991) Ischaemic heart disease in England and Wales around the year 2000. J Epidemiol Community Health 45:71–72. https://doi.org/10.1136/jech.45.1.71CrossRefPubMedPubMedCentral

20.

Stavreva DA, George AA, Klausmeyer P, Varticovski L, Sack D, Voss TC, Schiltz RL, Blazer VS, Iwanowicz LR, Hager GL (2012) Prevalent glucocorticoid and androgen activity in US water sources. Sci Rep 2:937. https://doi.org/10.1038/srep00937CrossRefPubMedPubMedCentral

21.

Hakim C, Padmanabhan V, Vyas AK (2017) Gestational hyperandrogenism in developmental programming. Endocrinology 158:199–212. https://doi.org/10.1210/en.2016-1801CrossRefPubMed

22.

Xita N, Tsatsoulis A (2006) Fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. J Clin Endocrinol Metabol 91:1660–1666. https://doi.org/10.1210/jc.2005-2757CrossRef

23.

Padmanabhan V, Manikkam M, Recabarren S, Foster D (2006) Prenatal testosterone excess programs reproductive and metabolic dysfunction in the female. Mol Cell Endocrinol 246:165–174. https://doi.org/10.1016/j.mce.2005.11.016CrossRefPubMed

24.

Amalfi S, Velez LM, Heber MF, Vighi S, Ferreira SR, Orozco AV, Pignataro O, Motta AB (2012) Prenatal hyperandrogenization induces metabolic and endocrine alterations which depend on the levels of testosterone exposure. PLoS ONE 7:e37658. https://doi.org/10.1371/journal.pone.0037658CrossRefPubMedPubMedCentral

25.

Nohara K, Liu S, Meyers MS, Waget A, Ferron M, Karsenty G, Burcelin R, Mauvais-Jarvis F (2013) Developmental androgen excess disrupts reproduction and energy homeostasis in adult male mice. J Endocrinol 219:259–268. https://doi.org/10.1530/joe-13-0230CrossRefPubMedPubMedCentral

26.

Eisner JR, Dumesic DA, Kemnitz JW, Abbott DH (2000) Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys. J Clin Endocrinol Metab 85:1206–1210. https://doi.org/10.1210/jcem.85.3.6453CrossRefPubMed

27.

Hague WM, Adams J, Rodda C, Brook CG, de Bruyn R, Grant DB, Jacobs HS (1990) The prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives. Clin Endocrinol (Oxf) 33:501–510. https://doi.org/10.1111/j.1365-2265.1990.tb03887.xCrossRefPubMed

28.

Barnes RB, Rosenfield RL, Ehrmann DA, Cara JF, Cuttler L, Levitsky LL, Rosenthal IM (1994) Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab 79:1328–1333. https://doi.org/10.1210/jcem.79.5.7962325CrossRefPubMed

29.

Tian S, Lin XH, Xiong YM, Liu ME, Yu TT, Lv M et al (2017) Prevalence of prediabetes risk in offspring born to mothers with hyperandrogenism. EBioMedicine 16:275–283. https://doi.org/10.1016/j.ebiom.2017.01.011CrossRefPubMedPubMedCentral

30.

Recabarren SE, Smith R, Rios R, Maliqueo M, Echiburu B, Codner E, Cassorla F, Rojas P, Sir-Petermann T (2008) Metabolic profile in sons of women with polycystic ovary syndrome. J Clin Endocrinol Metabol 93:1820–1826. https://doi.org/10.1210/jc.2007-2256CrossRef

31.

Torchen LC, Idkowiak J, Fogel NR, O’Neil DM, Shackleton CH, Arlt W, Dunaif A (2016) Evidence for increased 5α-reductase activity during early childhood in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 101:2069–2075. https://doi.org/10.1210/jc.2007-225610.1210/jc.2015-3926CrossRefPubMedPubMedCentral

32.

Yildiz BO, Yarali H, Oguz H, Bayraktar M (2003) Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:2031–2036. https://doi.org/10.1210/jc.2007-225610.1210/jc.2002-021499CrossRefPubMed

33.

Huang G, Cherkerzian S, Loucks EB, Buka SL, Handa RJ, Lasley BL, Bhasin S, Goldstein JM (2018) Sex differences in the prenatal programming of adult metabolic syndrome by maternal androgens. J Clin Endocrinol Metab 103:3945–3953. https://doi.org/10.1210/jc.2018-01243CrossRefPubMedPubMedCentral

34.

Risal S, Li C, Luo Q, Fornes R, Lu H, Eriksson G, Manti M, Ohlsson C, Lindgren E, Crisosto N, Maliqueo M, Echiburú B, Recabarren S, Petermann TS, Benrick A, Brusselaers N, Qiao J, Deng Q, Stener-Victorin E (2023) Transgenerational transmission of reproductive and metabolic dysfunction in the male progeny of polycystic ovary syndrome. Cell Rep Med 4:101035. https://doi.org/10.1016/j.xcrm.2023.101035CrossRefPubMedPubMedCentral

35.

Siemienowicz KJ, Filis P, Shaw S, Douglas A, Thomas J, Mulroy S, Howie F, Fowler PA, Duncan WC, Rae MT (2019) Fetal androgen exposure is a determinant of adult male metabolic health. Sci Rep 9:20195. https://doi.org/10.1038/s41598-019-56790-4CrossRefPubMedPubMedCentral

36.

Ober C, Loisel DA, Gilad Y (2008) Sex-specific genetic architecture of human disease. Nat Rev Genet 9:911–922. https://doi.org/10.1038/nrg2415CrossRefPubMedPubMedCentral

37.

Simerly RB (2002) Wired for reproduction: organization and development of sexually dimorphic circuits in the mammalian forebrain. Annu Rev Neurosci 25:507–536. https://doi.org/10.1146/annurev.neuro.25.112701.142745CrossRefPubMed

38.

Lansdown A, Rees DA (2012) The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target? Clin Endocrinol (Oxf) 77:791–801. https://doi.org/10.1111/cen.12003CrossRefPubMed

39.

Mauvais-Jarvis F (2014) Developmental androgenization programs metabolic dysfunction in adult mice: clinical implications. Adipocyte 3:151–154. https://doi.org/10.4161/adip.27746CrossRefPubMedPubMedCentral

40.

Culbert KM, Breedlove SM, Burt SA, Klump KL (2008) Prenatal hormone exposure and risk for eating disorders: a comparison of opposite-sex and same-sex twins. Arch Gen Psychiatry 65:329–336. https://doi.org/10.1001/archgenpsychiatry.2007.47CrossRefPubMedPubMedCentral

41.

Wah CS (2016) Gender differences in eating behaviour. Int J Bus Econ Man 4:116–121. https://doi.org/10.24924/ijabm/2016.11/v4.iss2/116.121CrossRef

42.

Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT (2011) Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol 40:189–207. https://doi.org/10.1093/ije/dyq158CrossRefPubMed

43.

Navarro G, Allard C, Xu W, Mauvais-Jarvis F (2015) The role of androgens in metabolism, obesity, and diabetes in males and females. Obesity (Silver Spring) 23:713–719. https://doi.org/10.1002/oby.21033CrossRefPubMed

44.

Zitzmann M, Faber S, Nieschlag E (2006) Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 91:4335–4343. https://doi.org/10.1210/jc.2006-0401CrossRefPubMed

45.

Zitzmann M (2009) Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 5:673–681. https://doi.org/10.1038/nrendo.2009.212CrossRefPubMed

46.

Ding EL, Song Y, Malik VS, Liu S (2006) Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 295:1288–1299. https://doi.org/10.1001/jama.295.11.1288CrossRefPubMed

47.

Liu PY, Death AK, Handelsman DJ (2003) Androgens and cardiovascular disease. Endocr Rev 24:313–340. https://doi.org/10.1210/er.2003-0005CrossRefPubMed

48.

Legro RS, Kunselman AR, Dodson WC, Dunaif A (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165–169. https://doi.org/10.1210/jcem.84.1.5393CrossRefPubMed

49.

Alexanderson C, Eriksson E, Stener-Victorin E, Lystig T, Gabrielsson B, Lönn M, Holmäng A (2007) Postnatal testosterone exposure results in insulin resistance, enlarged mesenteric adipocytes, and an atherogenic lipid profile in adult female rats: comparisons with estradiol and dihydrotestosterone. Endocrinology 148:5369–5376. https://doi.org/10.1210/en.2007-0305CrossRefPubMed

50.

Nilsson C, Niklasson M, Eriksson E, Björntorp P, Holmäng A (1998) Imprinting of female offspring with testosterone results in insulin resistance and changes in body fat distribution at adult age in rats. J Clin Invest 101:74–78. https://doi.org/10.1172/jci1353CrossRefPubMedPubMedCentral

51.

Chen X, McClusky R, Chen J, Beaven SW, Tontonoz P, Arnold AP, Reue K (2012) The number of x chromosomes causes sex differences in adiposity in mice. PLoS Genet 8:e1002709. https://doi.org/10.1371/journal.pgen.1002709CrossRefPubMedPubMedCentral

52.

Tiffin GJ, Rieger D, Betteridge KJ, Yadav BR, King WA (1991) Glucose and glutamine metabolism in pre-attachment cattle embryos in relation to sex and stage of development. J Reprod Fertil 93:125–132. https://doi.org/10.1530/jrf.0.0930125CrossRefPubMed

53.

Chen X, McClusky R, Itoh Y, Reue K, Arnold AP (2013) X and Y chromosome complement influence adiposity and metabolism in mice. Endocrinology 154:1092–1104. https://doi.org/10.1210/en.2012-2098CrossRefPubMedPubMedCentral

54.

Bojesen A, Høst C, Gravholt CH (2010) Klinefelter’s syndrome, type 2 diabetes and the metabolic syndrome: the impact of body composition. Mol Hum Reprod 16:396–401. https://doi.org/10.1093/molehr/gaq016CrossRefPubMed

55.

Bojesen A, Kristensen K, Birkebaek NH, Fedder J, Mosekilde L, Bennett P, Laurberg P, Frystyk J, Flyvbjerg A, Christiansen JS, Gravholt CH (2006) The metabolic syndrome is frequent in Klinefelter’s syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care 29:1591–1598. https://doi.org/10.2337/dc06-0145CrossRefPubMed

56.

Link JC, Chen X, Arnold AP, Reue K (2013) Metabolic impact of sex chromosomes Adipocyte 2:74–79. https://doi.org/10.4161/adip.23320CrossRefPubMed

57.

Wolf CJ, Hotchkiss A, Ostby JS, LeBlanc GA, Gray LE Jr (2002) Effects of prenatal testosterone propionate on the sexual development of male and female rats: a dose-response study. Toxicol Sci 65:71–86. https://doi.org/10.1093/toxsci/65.1.71CrossRefPubMed

58.

Ashraf S, Nabi M, Rashid F, Amin S (2019) Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review. Egypt J Med Hum Gene 20:1–10. https://doi.org/10.1186/s43042-019-0031-4CrossRef

59.

Franks S, McCarthy MI, Hardy K (2006) Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl 29:278–285. https://doi.org/10.1111/j.1365-2605.2005.00623.x. (discussion 286-290)CrossRefPubMed

60.

Barsky M, Merkison J, Hosseinzadeh P, Yang L, Bruno-Gaston J, Dunn J, Gibbons W, Blesson CS (2021) Fetal programming of polycystic ovary syndrome: effects of androgen exposure on prenatal ovarian development. J Steroid Biochem Mol Biol 207:105830. https://doi.org/10.1016/j.jsbmb.2021.105830CrossRefPubMedPubMedCentral

61.

Cesta CE, Öberg AS, Ibrahimson A, Yusuf I, Larsson H, Almqvist C, D’Onofrio BM, Bulik CM, Fernández de la Cruz L, Mataix-Cols D, Landén M, Rosenqvist MA (2020) Maternal polycystic ovary syndrome and risk of neuropsychiatric disorders in offspring: prenatal androgen exposure or genetic confounding? Psychol Med 50:616–624. https://doi.org/10.1017/s0033291719000424CrossRefPubMed

62.

Daan NM, Koster MP, Steegers-Theunissen RP, Eijkemans MJ, Fauser BC (2017) Endocrine and cardiometabolic cord blood characteristics of offspring born to mothers with and without polycystic ovary syndrome. Fertil Steril 107:261–268. https://doi.org/10.1016/j.fertnstert.2016.09.042CrossRefPubMed

63.

Mehrabian F, Kelishadi R (2012) Comparison of the metabolic parameters and androgen level of umbilical cord blood in newborns of mothers with polycystic ovary syndrome and controls. J Res Med Sci 17:207–211PubMedPubMedCentral

64.

Barry JA, Kay AR, Navaratnarajah R, Iqbal S, Bamfo JE, David AL, Hines M, Hardiman PJ (2010) Umbilical vein testosterone in female infants born to mothers with polycystic ovary syndrome is elevated to male levels. J Obstet Gynaecol 30:444–446. https://doi.org/10.3109/01443615.2010.485254CrossRefPubMed

65.

Palomba S, Russo T, Falbo A, Di Cello A, Tolino A, Tucci L, La Sala GB, Zullo F (2013) Macroscopic and microscopic findings of the placenta in women with polycystic ovary syndrome. Hum Reprod 28:2838–2847. https://doi.org/10.1093/humrep/det250CrossRefPubMed

66.

Maliqueo M, Lara HE, Sánchez F, Echiburú B, Crisosto N, Sir-Petermann T (2013) Placental steroidogenesis in pregnant women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 166:151–155. https://doi.org/10.1016/j.ejogrb.2012.10.015CrossRefPubMed

67.

Beckett EM, Astapova O, Steckler TL, Veiga-Lopez A, Padmanabhan V (2014) Developmental programing: impact of testosterone on placental differentiation. Reproduction 148:199–209. https://doi.org/10.1530/rep-14-0055CrossRefPubMedPubMedCentral

68.

Padmanabhan V, Veiga-Lopez A (2013) Animal models of the polycystic ovary syndrome phenotype. Steroids 78:734–740. https://doi.org/10.1016/j.steroids.2013.05.004CrossRefPubMedPubMedCentral

Title: Preconceptional maternal hyperandrogenism and metabolic syndrome risk in male offspring: a long-term population-based study
Authors: M. Noroozzadeh
M. Rahmati
M. Amiri
M. Saei Ghare Naz
F. Azizi
F. Ramezani Tehrani
Publication date: 22-04-2024
Publisher: Springer International Publishing
Keywords: Androgens
Testosterone
Published in: Journal of Endocrinological Investigation
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-024-02374-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com